Biomarkers at the onset of GVHD symptoms. (A-C) REG3α, HGF, and KRT18 concentrations, respectively, at the onset of symptoms consistent with GVHD in 954 HCT patients. (D) ROC curves comparing biomarker concentrations at the onset of LGI GVHD without liver GVHD (n = 144) and non-GVHD diarrhea (n = 42). REG3α (thin solid line): AUC = 0.79; HGF (dotted line): AUC = 0.60; KRT18 (dashed line): AUC = 0.60; composite of all 3 biomarkers (thick solid line): AUC = 0.80. (E-G) NRM in patients with LGI GVHD at onset with onset concentrations above the median (solid line; n = 89) versus patients with onset concentrations below the median (dotted line; n = 89) for REG3a, HGF, and KRT18, respectively. (E) REG3a: > 135 ng/mL versus ≤ 135 ng/mL; 52% versus 33%, P = .01. (F) HGF: > 1398 pg/mL versus ≤ 1398 pg/mL; 52% versus 33%, P = .02. (G) KRT18 > 373 U/L versus ≤ 373 U/L; 47% versus 38%, P = .3. (H) ROC curves comparing biomarker concentrations at the onset of liver GVHD without GI GVHD (n = 16) and non-GVHD liver complications (n = 25); REG3α (thin solid line): AUC = 0.61; HGF (dotted line): AUC = 0.59; KRT18 (dashed line): AUC = 0.63; composite of all 3 biomarkers (thick solid line): AUC = 0.62.